These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9416320)
21. Vascular responses to vasopressin antagonists in man and rat. Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989 [TBL] [Abstract][Full Text] [Related]
22. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959 [TBL] [Abstract][Full Text] [Related]
23. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. Nishikimi T; Kawano Y; Saito Y; Matsuoka H J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428 [TBL] [Abstract][Full Text] [Related]
24. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition. Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757 [TBL] [Abstract][Full Text] [Related]
25. Neuroprotective effects of nimodipine and MK-801 on acute infectious brain edema induced by injection of pertussis bacilli to neocortex of rats. Chen LH; Liu LX; Yang YJ; Liu YS; Cao MH Chin J Traumatol; 2003 Apr; 6(2):118-23. PubMed ID: 12659709 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. Ohnishi A; Ko Y; Fujihara H; Miyamoto G; Okada K; Odomi M J Clin Pharmacol; 1993 Mar; 33(3):230-8. PubMed ID: 8385161 [TBL] [Abstract][Full Text] [Related]
27. Human internal mammary artery responses to non-peptide vasopressin antagonists. Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263 [TBL] [Abstract][Full Text] [Related]
28. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice. Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173 [TBL] [Abstract][Full Text] [Related]
29. Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist. Kulkarni P; Bhosle MR; Lu SF; Simon NS; Iriah S; Brownstein MJ; Ferris CF Brain Res Bull; 2020 Dec; 165():218-227. PubMed ID: 33053434 [TBL] [Abstract][Full Text] [Related]
30. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936 [TBL] [Abstract][Full Text] [Related]
31. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553 [TBL] [Abstract][Full Text] [Related]
32. Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats. Okada H; Suzuki H; Kanno Y; Saruta T J Cardiovasc Pharmacol; 1995 May; 25(5):847-52. PubMed ID: 7630164 [TBL] [Abstract][Full Text] [Related]
33. Brain edema, autoregulation, and calcium antagonism. An experimental study with nimodipine. Gaab MR; Höllerhage HG; Walter GF; Hocheder M; Haubitz I Adv Neurol; 1990; 52():391-400. PubMed ID: 2118717 [TBL] [Abstract][Full Text] [Related]
34. Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat. Fraser TB; Turner SW; Wen C; Li M; Burrell LM; Whitworth JA Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):866-70. PubMed ID: 11071300 [TBL] [Abstract][Full Text] [Related]
35. Protective effect of the N-methyl-D-aspartate receptor antagonists, MK-801 and CPP on cold-induced brain oedema. Görgülü A; Kiriş T; Unal F; Türkoğlu U; Küçük M; Cobanoğlu S Acta Neurochir (Wien); 1999; 141(1):93-8. PubMed ID: 10071692 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice. Zeynalov E; Jones SM; Elliott JP PLoS One; 2017; 12(8):e0183985. PubMed ID: 28854286 [TBL] [Abstract][Full Text] [Related]
37. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats. Fujisawa Y; Miyatake A; Hayashida Y; Aki Y; Kimura S; Tamaki T; Abe Y Am J Physiol; 1994 Nov; 267(5 Pt 2):H1713-8. PubMed ID: 7977803 [TBL] [Abstract][Full Text] [Related]
38. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435 [TBL] [Abstract][Full Text] [Related]
39. Effect of parenteral nutrition on cold-induced vasogenic edema in cats. Waters DC; Hoff JT; Black KL J Neurosurg; 1986 Mar; 64(3):460-5. PubMed ID: 3081694 [TBL] [Abstract][Full Text] [Related]
40. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone. Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]